← Back to Screener
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Price$4.33
Favorite Metrics
Price vs S&P 500 (26W)172.60%
Price vs S&P 500 (4W)32.03%
Market Capitalization$708.49M
P/E Ratio (Annual)29.50x
All Metrics
P/CF (Annual)5.58x
Book Value / Share (Quarterly)$4.55
P/TBV (Annual)2.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-10.32%
Cash Flow / Share (Quarterly)$0.78
Price vs S&P 500 (YTD)27.03%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)8.11%
EPS (TTM)$0.11
10-Day Avg Trading Volume1.80M
EPS Excl Extra (TTM)$0.11
Revenue Growth (5Y)-5.33%
EPS (Annual)$0.15
ROI (Annual)16.69%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-9.53%
Cash / Share (Quarterly)$1.32
P/E Basic Excl Extra (TTM)29.50x
Revenue Growth QoQ (YoY)-47.31%
EPS Growth (5Y)-25.92%
P/E Normalized (Annual)29.50x
ROA (Last FY)6.05%
Revenue Growth TTM (YoY)-15.72%
EBITD / Share (TTM)$0.63
ROE (5Y Avg)-206.33%
Operating Margin (TTM)33.26%
Cash Flow / Share (Annual)$0.78
P/B Ratio1.00x
P/B Ratio (Quarterly)2.31x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.64x
Net Interest Coverage (TTM)3.44x
ROA (TTM)6.57%
EPS Growth QoQ (YoY)889.04%
EV / EBITDA (TTM)10.72x
EPS Incl Extra (Annual)$0.15
Current Ratio (Annual)1.13x
Quick Ratio (Quarterly)1.08x
3-Month Avg Trading Volume3.88M
52-Week Price Return574.49%
EV / Free Cash Flow (Annual)8.49x
P/E Incl Extra (TTM)29.50x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$-2.10
P/S Ratio (Annual)2.39x
Asset Turnover (Annual)0.75x
52-Week High$5.78
Operating Margin (5Y Avg)-7.34%
EPS Excl Extra (Annual)$0.15
CapEx CAGR (5Y)-54.79%
26-Week Price Return176.58%
Quick Ratio (Annual)1.08x
13-Week Price Return-2.24%
Total Debt / Equity (Annual)0.61x
Current Ratio (Quarterly)1.13x
Enterprise Value$1,077.712
Revenue / Share Growth (5Y)-5.60%
Asset Turnover (TTM)0.81x
Book Value / Share Growth (5Y)44.86%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)79.67x
Pretax Margin (Annual)23.65%
Cash / Share (Annual)$1.32
3-Month Return Std Dev88.39%
Gross Margin (5Y Avg)96.84%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-7.26%
EBITDA Interim CAGR (5Y)-32.37%
ROE (Last FY)26.83%
Net Interest Coverage (Annual)3.44x
EPS Basic Excl Extra (Annual)$0.15
P/FCF (TTM)4.99x
Receivables Turnover (TTM)4.60x
EV / Free Cash Flow (TTM)8.49x
Total Debt / Equity (Quarterly)0.56x
EPS Incl Extra (TTM)$0.11
Receivables Turnover (Annual)4.60x
ROI (TTM)17.90%
P/S Ratio (TTM)2.39x
Pretax Margin (5Y Avg)-12.39%
Revenue / Share (Annual)$1.82
Tangible BV / Share (Annual)$4.24
Forward P/E3.40x
Free OCF CAGR (5Y)-5.33%
Price vs S&P 500 (52W)544.66%
P/E Ratio (TTM)29.50x
EPS Growth TTM (YoY)2150.00%
Year-to-Date Return29.67%
5-Day Price Return21.39%
EPS Normalized (Annual)$0.15
ROA (5Y Avg)-28.73%
Net Profit Margin (Annual)8.11%
Month-to-Date Return24.50%
Cash Flow / Share (TTM)$-5.48
EBITD / Share (Annual)$0.62
EPS Growth (3Y)-46.07%
Operating Margin (Annual)33.26%
LT Debt / Equity (Annual)0.61x
P/CF (TTM)5.58x
ROI (5Y Avg)8.20%
P/E Excl Extra (TTM)29.50x
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$0.11
P/B Ratio (Annual)2.91x
Inventory Turnover (TTM)16.12x
Pretax Margin (TTM)23.65%
Book Value / Share (Annual)$4.24
Price vs S&P 500 (13W)-2.92%
Net Margin Growth (5Y)-21.54%
Beta0.31x
P/FCF (Annual)5.58x
Revenue / Share (TTM)$2.45
ROE (TTM)29.31%
52-Week Low$0.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.44
3.90
3.90
3.90
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IRWDIronwood Pharmaceuticals, Inc. - Class A | 2.39x | -15.72% | 100.00% | -25.92% | $4.33 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. The company markets LINZESS and CONSTELLA (both linaclotide) for the treatment of irritable bowel syndrome with constipation, chronic constipation, and functional constipation across North America, Europe, and Asia-Pacific regions.